Journal
NATURE MEDICINE
Volume 10, Issue 2, Pages 145-147Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nm988
Keywords
-
Funding
- NCI NIH HHS [P01 CA080124-070006, P01 CA080124-029001, R21 CA099237-02, R21 CA099237, P01 CA080124-01A1S19001, P01 CA080124-020002, P01 CA080124-049001, P01 CA080124-06A20006, P01 CA080124, P01 CA080124-030002, P01 CA080124-089001, P01 CA80124, P01 CA080124-01A19001, P01 CA080124-059001, P01 CA080124-039001, P01 CA080124-06A29001, P01 CA080124-040002, P01 CA080124-079001, P01 CA080124-050002, P01 CA080124-01A10002, P01 CA080124-080006, P01 CA080124-01A1S10002] Funding Source: Medline
Ask authors/readers for more resources
The effects of vascular endothelial growth factor (VEGF) blockade on the vascular biology of human tumors are not known. Here we show here that a single infusion of the VEGF-specific antibody bevacizumab decreases tumor perfusion, vascular volume, microvascular density, interstitial fluid pressure and the number of viable, circulating endothelial and progenitor cells, and increases the fraction of vessels with pericyte coverage in rectal carcinoma patients. These data indicate that VEGF blockade has a direct and rapid antivascular effect in human tumors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available